Alvotech
ALVO Healthcare Drug Manufacturers Specialty & Generic
Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,311.0%, EPS fell 99.5%, free cash flow fell 496.6% and total debt rose 16.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow ALVO
Alvotech (ALVO) P/E ratio
Alvotech has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 999× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 76.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | n/m |
| PRGO Perrigo Company plc compare | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. compare | n/m |
| ALVO Alvotech | n/m |
| SUPN Supernus Pharmaceuticals, Inc. compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| PBH Prestige Consumer Healthcare Inc. compare | 13.9× |
| ANIP ANI Pharmaceuticals, Inc. compare | 14.9× |
| PAHC Phibro Animal Health Corporation compare | 15.8× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)